Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) Short Interest Up 2,523.8% in January

Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) was the target of a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 55,100 shares, an increase of 2,523.8% from the January 15th total of 2,100 shares. Based on an average trading volume of 171,000 shares, the days-to-cover ratio is presently 0.3 days.

Enzon Pharmaceuticals Stock Down 6.9 %

Shares of ENZN stock traded down $0.01 on Wednesday, hitting $0.16. The stock had a trading volume of 32,220 shares, compared to its average volume of 62,793. Enzon Pharmaceuticals has a one year low of $0.06 and a one year high of $0.24. The business has a 50 day moving average price of $0.15 and a 200 day moving average price of $0.13. The company has a market cap of $12.02 million, a PE ratio of 16.22 and a beta of 0.26.

Enzon Pharmaceuticals Company Profile

Enzon Pharmaceuticals, Inc, together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs.